Effect of nateglinide on the incidence of diabetes and cardiovascular events

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

  • Rury R Holman
  • Steven M Haffner
  • John J McMurray
  • M Angelyn Bethel
  • Björn Holzhauer
  • Tsushung A Hua
  • Yuri Belenkov
  • Mitradev Boolell
  • John B Buse
  • Brendan M Buckley
  • Antonio R Chacra
  • Fu-Tien Chiang
  • Bernard Charbonnel
  • Chun-Chung Chow
  • Melanie J Davies
  • Prakash Deedwania
  • Peter Diem
  • Daniel Einhorn
  • Vivian Fonseca
  • Gregory R Fulcher
  • Zbigniew Gaciong
  • Sonia Gaztambide
  • Thomas Giles
  • Edward Horton
  • Hasan Ilkova
  • Trond Jenssen
  • Steven E Kahn
  • Henry Krum
  • Markku Laakso
  • Lawrence A Leiter
  • Naomi S Levitt
  • Viacheslav Mareev
  • Felipe Martinez
  • Chantal Masson
  • Theodore Mazzone
  • Eduardo Meaney
  • Richard Nesto
  • Changyu Pan
  • Rudolf Prager
  • Sotirios A Raptis
  • Guy E H M Rutten
  • Herbert Sandstroem
  • Frank Schaper
  • Andre Scheen
  • Ole Schmitz
  • Isaac Sinay
  • Vladimir Soska
  • Stender, Steen
  • Gyula Tamás
  • Gianni Tognoni
  • NAVIGATOR Study Group
The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown.
OriginalsprogEngelsk
TidsskriftBriefings from the New England Journal of Medicine
Vol/bind362
Udgave nummer16
Sider (fra-til)1463-76
Antal sider14
ISSN1531-7242
DOI
StatusUdgivet - 22 apr. 2010

ID: 34066155